Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | l(3)mbt-like 1 (Drosophila) | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_130415 | All targets in OG5_130415 |
Schistosoma japonicum | Lethal(3)malignant brain tumor-like 3 protein, putative | Get druggable targets OG5_130415 | All targets in OG5_130415 |
Echinococcus granulosus | endonuclease exonuclease phosphatase | Get druggable targets OG5_130415 | All targets in OG5_130415 |
Schistosoma japonicum | Lethal(3)malignant brain tumor-like 4 protein, putative | Get druggable targets OG5_130415 | All targets in OG5_130415 |
Echinococcus multilocularis | endonuclease exonuclease phosphatase | Get druggable targets OG5_130415 | All targets in OG5_130415 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | acetylcholinesterase | 0.023 | 0.5773 | 1 |
Echinococcus multilocularis | endonuclease exonuclease phosphatase | 0.0227 | 0.5672 | 0.9824 |
Echinococcus granulosus | carboxylesterase 5A | 0.023 | 0.5773 | 1 |
Echinococcus granulosus | endonuclease exonuclease phosphatase | 0.0227 | 0.5672 | 0.9824 |
Echinococcus granulosus | acetylcholinesterase | 0.023 | 0.5773 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.023 | 0.5773 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.023 | 0.5773 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.023 | 0.5773 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.023 | 0.5773 | 0.5773 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.023 | 0.5773 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.023 | 0.5773 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.023 | 0.5773 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.023 | 0.5773 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.023 | 0.5773 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.023 | 0.5773 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 3.1623 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of L3MBTL1. (Class of assay: confirmatory) [Related pubchem assays: 485292 (Probe Development Summary for Inhibitors of L3MBTL1)] | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.